Affimed N.V.

NASDAQ:AFMD

4 (USD) • At close September 13, 2024
Bedrijfsnaam Affimed N.V.
Symbool AFMD
Munteenheid USD
Prijs 4
Beurswaarde 60,910,000
Dividendpercentage 0%
52-weken bereik 2.24 - 8.95
Industrie Biotechnology
Sector Healthcare
CEO Dr. Adi Hoess M.D., Ph.D.
Website https://www.affimed.com

An error occurred while fetching data.

Over Affimed N.V.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase

Vergelijkbare Aandelen

Y-mAbs Therapeutics, Inc. logo

Y-mAbs Therapeutics, Inc.

YMAB

13.74 USD

SI-BONE, Inc. logo

SI-BONE, Inc.

SIBN

15.73 USD

Computer Programs and Systems, Inc. logo

Computer Programs and Systems, Inc.

CPSI

9.19 USD

GH Research PLC logo

GH Research PLC

GHRS

8.3 USD

PetMed Express, Inc. logo

PetMed Express, Inc.

PETS

3.59 USD

AirSculpt Technologies, Inc. logo

AirSculpt Technologies, Inc.

AIRS

4.03 USD

PetIQ, Inc. logo

PetIQ, Inc.

PETQ

30.68 USD

Ocugen, Inc. logo

Ocugen, Inc.

OCGN

1.21 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)